Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests
JOHN D. BRUNZELL,
R. PAUL ROBERTSON,
ROGER L. LERNER,
WILLIAM R. HAZZARD,
JOHN W. ENSINCK,
EDWIN L. BIERMAN and
DANIEL PORTE, JR.
The Department of Medicine, University of Washington School of Medicine, and the Veterans Administration Hospital Seattle, Washington
Reprints: Dr. Brunzell, Veterans Administration Hospital, 4435 Beacon Avenue South, Seattle, Washington 98108.
Insulin secretion and glucose disappearance rate were measuredin 66 subjects with a wide range of fasting plasma glucose levels.The acute insulin response was present in subjects with fastingglucose levels below 115 mg/dl but was absent above this level.The glucose disappearance rate related to the relative acuteinsulin response in subjects with fasting glucose below 115mg/dl and to total insulin response when fasting glucose levelswere above 115 mg/dl. A calculated glucose disappearance rateof 1.06 per cent per minute was found when the acute insulinresponse was zero. All subjects with fasting glucose levels> 115 mg/dl had glucose disappearance rates < 1.06. Thesestudies support 1) epidemiological data indicating 115 mg/dlas an upper limit of normal for fasting plasma glucose levelsand 1.0 per cent per minute as a lower limit of normal for theglucose disappearance rate, and 2) evidence for an importantrole for the acute insulin response the determination of glucosedisappearance rates during intravenous glucose tolerance tests.
Received February 26, 1975.
This article has been cited by other articles:
R. G. Bretzel, M. Eckhard, W. Landgraf, D. R. Owens, and T. Linn Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
Diabetes Care,
November 1, 2009;
32(suppl_2):
S260 - S265.
[Full Text][PDF]
L. F. Meneghini Early Insulin Treatment in Type 2 Diabetes: What are the pros?
Diabetes Care,
November 1, 2009;
32(suppl_2):
S266 - S269.
[Full Text][PDF]
J. J. Meier, B. A. Menge, T. G.K. Breuer, C. A. Muller, A. Tannapfel, W. Uhl, W. E. Schmidt, and H. Schrader Functional Assessment of Pancreatic {beta}-Cell Area in Humans
Diabetes,
July 1, 2009;
58(7):
1595 - 1603.
[Abstract][Full Text][PDF]
K. Aaboe, F. K. Knop, T. Vilsboll, A. Volund, U. Simonsen, C. F. Deacon, S. Madsbad, J. J. Holst, and T. Krarup KATP Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
February 1, 2009;
94(2):
603 - 608.
[Abstract][Full Text][PDF]
Z. T. Bloomgarden American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three
Diabetes Care,
December 1, 2008;
31(12):
2404 - 2409.
[Full Text][PDF]
S.-P. Choukem, E. Sobngwi, L.-S. Fetita, P. Boudou, E. De Kerviler, Y. Boirie, I. Hainault, P. Vexiau, F. Mauvais-Jarvis, F. Calvo, et al. Multitissue Insulin Resistance Despite Near-Normoglycemic Remission in Africans With Ketosis-Prone Diabetes
Diabetes Care,
December 1, 2008;
31(12):
2332 - 2337.
[Abstract][Full Text][PDF]
M. J. Franz Themed Review: Lifestyle Interventions Across the Continuum of Type 2 Diabetes: Reducing the Risks of Diabetes
American Journal of Lifestyle Medicine,
October 1, 2007;
1(5):
327 - 334.
[Abstract][PDF]
R. P. Robertson Estimation of {beta}-Cell Mass by Metabolic Tests: Necessary, but How Sufficient?
Diabetes,
October 1, 2007;
56(10):
2420 - 2424.
[Abstract][Full Text][PDF]
M. R. Rickels, M. Kamoun, J. Kearns, J. F. Markmann, and A. Naji Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on {beta}-Cell Secretory Capacity
J. Clin. Endocrinol. Metab.,
July 1, 2007;
92(7):
2410 - 2414.
[Abstract][Full Text][PDF]
L. Blonde Easing the Transition to Insulin Therapy in People With Type 2 Diabetes
The Diabetes Educator,
July 1, 2007;
33(Supplement_7):
232S - 240S.
[Full Text][PDF]
B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev.,
April 1, 2007;
28(2):
187 - 218.
[Abstract][Full Text][PDF]
G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, and R. Rizza Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes
Diabetes,
April 1, 2007;
56(4):
1113 - 1119.
[Abstract][Full Text][PDF]
B. Ahren Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects
Diabetes Care,
March 1, 2007;
30(3):
644 - 648.
[Abstract][Full Text][PDF]
S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation.
The Diabetes Educator,
June 1, 2006;
32(Supplement_4):
137S - 145S.
[Full Text][PDF]
J. E. Shaw, P. Z. Zimmet, and K. G. M.M. Alberti Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion
Diabetes Care,
May 1, 2006;
29(5):
1170 - 1172.
[Full Text][PDF]
K. M. Utzschneider, R. L. Prigeon, D. B. Carr, R. L. Hull, J. Tong, J. B. Shofer, B. M. Retzlaff, R. H. Knopp, and S. E. Kahn Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses
Diabetes Care,
February 1, 2006;
29(2):
356 - 362.
[Abstract][Full Text][PDF]
J.-C. Henquin, M. Nenquin, P. Stiernet, and B. Ahren In Vivo and In Vitro Glucose-Induced Biphasic Insulin Secretion in the Mouse: Pattern and Role of Cytoplasmic Ca2+ and Amplification Signals in {beta}-Cells
Diabetes,
February 1, 2006;
55(2):
441 - 451.
[Abstract][Full Text][PDF]
F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
November 1, 2005;
90(11):
5991 - 5997.
[Abstract][Full Text][PDF]
C. Kjorholt, M. C. Akerfeldt, T. J. Biden, and D. R. Laybutt Chronic Hyperglycemia, Independent of Plasma Lipid Levels, Is Sufficient for the Loss of {beta}-Cell Differentiation and Secretory Function in the db/db Mouse Model of Diabetes
Diabetes,
September 1, 2005;
54(9):
2755 - 2763.
[Abstract][Full Text][PDF]
S. Del Prato, R. Miccoli, and G. Penno Review: The importance of effective early phase insulin secretion
The British Journal of Diabetes & Vascular Disease,
July 1, 2005;
5(4):
198 - 202.
[Abstract][PDF]
L. S. Cozma, S. D. Luzio, G. J. Dunseath, P. M. Underwood, and D. R. Owens {beta}-Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients
Diabetes Care,
May 1, 2005;
28(5):
1001 - 1007.
[Abstract][Full Text][PDF]
C. Abletshauser, P. Brunel, K.-H. Usadel, and M. Hanefeld Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease,
March 1, 2005;
5(2):
93 - 99.
[Abstract][PDF]
M. O. Larsen, C. B. Juhl, N. Porksen, C. F. Gotfredsen, R. D. Carr, U. Ribel, M. Wilken, and B. Rolin {beta}-Cell function and islet morphology in normal, obese, and obese {beta}-cell mass-reduced Gottingen minipigs
Am J Physiol Endocrinol Metab,
February 1, 2005;
288(2):
E412 - E421.
[Abstract][Full Text][PDF]
M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff {beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Diabetes,
January 1, 2005;
54(1):
100 - 106.
[Abstract][Full Text][PDF]
G. C. Weir and S. Bonner-Weir Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes
Diabetes,
December 1, 2004;
53(suppl_3):
S16 - S21.
[Abstract][Full Text][PDF]
Y. Li, W. Xu, Z. Liao, B. Yao, X. Chen, Z. Huang, G. Hu, and J. Weng Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of {beta}-Cell Function
Diabetes Care,
November 1, 2004;
27(11):
2597 - 2602.
[Abstract][Full Text][PDF]
A. H. Xiang, R. K. Peters, S. L. Kjos, J. Goico, C. Ochoa, A. Marroquin, S. Tan, H. N. Hodis, S. P. Azen, and T. A. Buchanan Pharmacological Treatment of Insulin Resistance at Two Different Stages in the Evolution of Type 2 Diabetes: Impact on Glucose Tolerance and {beta}-Cell Function
J. Clin. Endocrinol. Metab.,
June 1, 2004;
89(6):
2846 - 2851.
[Abstract][Full Text][PDF]
E. A. Ryan, S. Imes, and C. Wallace Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
Diabetes Care,
May 1, 2004;
27(5):
1028 - 1032.
[Abstract][Full Text][PDF]
R. P. Robertson Consequences on {beta}-Cell Function and Reserve After Long-Term Pancreas Transplantation
Diabetes,
March 1, 2004;
53(3):
633 - 644.
[Abstract][Full Text][PDF]
A. Omer, V. F. Duvivier-Kali, W. Aschenbach, V. Tchipashvili, L. J. Goodyear, and G. C. Weir Exercise Induces Hypoglycemia in Rats With Islet Transplantation
Diabetes,
February 1, 2004;
53(2):
360 - 365.
[Abstract][Full Text]
J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001
Diabetes,
January 1, 2004;
53(1):
250 - 264.
[Abstract][Full Text][PDF]
E. V. Polyzogopoulou, F. Kalfarentzos, A. G. Vagenakis, and T. K. Alexandrides Restoration of Euglycemia and Normal Acute Insulin Response to Glucose in Obese Subjects With Type 2 Diabetes Following Bariatric Surgery
Diabetes,
May 1, 2003;
52(5):
1098 - 1103.
[Abstract][Full Text][PDF]
D. R. Laybutt, M. Glandt, G. Xu, Y. B. Ahn, N. Trivedi, S. Bonner-Weir, and G. C. Weir Critical Reduction in beta -Cell Mass Results in Two Distinct Outcomes over Time. ADAPTATION WITH IMPAIRED GLUCOSE TOLERANCE OR DECOMPENSATED DIABETES
J. Biol. Chem.,
January 24, 2003;
278(5):
2997 - 3005.
[Abstract][Full Text][PDF]
R. A Defronzo Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?
The British Journal of Diabetes & Vascular Disease,
January 1, 2003;
3(1_suppl):
S24 - S40.
[Abstract][PDF]
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Diabetes Care,
January 1, 2003;
26(90001):
s5 - 20.
[Full Text][PDF]
Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002
Diabetes Care,
September 1, 2002;
25(9):
1644 - 1649.
[Full Text][PDF]
T. A. Buchanan, A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. N. Hodis, et al. Preservation of Pancreatic {beta}-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women
Diabetes,
September 1, 2002;
51(9):
2796 - 2803.
[Abstract][Full Text][PDF]
D. R. Laybutt, A. Sharma, D. C. Sgroi, J. Gaudet, S. Bonner-Weir, and G. C. Weir Genetic Regulation of Metabolic Pathways in beta -Cells Disrupted by Hyperglycemia
J. Biol. Chem.,
March 22, 2002;
277(13):
10912 - 10921.
[Abstract][Full Text][PDF]
O. Schmitz, S. Lund, P. H. Andersen, M. Jonler, and N. Porksen Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes: A randomized double-blind study with repaglinide
Diabetes Care,
February 1, 2002;
25(2):
342 - 346.
[Abstract][Full Text][PDF]
S. Del Prato, P. Marchetti, and R. C. Bonadonna Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes
Diabetes,
February 1, 2002;
51(90001):
S109 - 116.
[Abstract][Full Text][PDF]
J. E. Gerich Is Reduced First-Phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes?
Diabetes,
February 1, 2002;
51(90001):
S117 - 121.
[Abstract][Full Text][PDF]
S. E. Kahn, B. Montgomery, W. Howell, M. Ligueros-Saylan, C.-H. Hsu, D. Devineni, J. F. McLeod, A. Horowitz, and J. E. Foley Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab.,
December 1, 2001;
86(12):
5824 - 5829.
[Abstract][Full Text][PDF]
S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
September 1, 2001;
86(9):
4047 - 4058.
[Full Text][PDF]
J. R. Singleton, A. G. Smith, and M. B. Bromberg Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy
Diabetes Care,
August 1, 2001;
24(8):
1448 - 1453.
[Abstract][Full Text][PDF]
P. A. Hollander, S. L. Schwartz, M. R. Gatlin, S. J. Haas, H. Zheng, J. E. Foley, and B. E. Dunning Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
Diabetes Care,
June 1, 2001;
24(6):
983 - 988.
[Abstract][Full Text]
E. A. Ryan, J. R.T. Lakey, R. V. Rajotte, G. S. Korbutt, T. Kin, S. Imes, A. Rabinovitch, J. F. Elliott, D. Bigam, N. M. Kneteman, et al. Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton Protocol
Diabetes,
April 1, 2001;
50(4):
710 - 719.
[Abstract][Full Text]
C. E. Gleason, M. Gonzalez, J. S. Harmon, and R. P. Robertson Determinants of glucose toxicity and its reversibility in the pancreatic islet beta -cell line, HIT-T15
Am J Physiol Endocrinol Metab,
November 1, 2000;
279(5):
E997 - E1002.
[Abstract][Full Text][PDF]
M. E. Røder, D. Porte Jr., R. S. Schwartz, and S. E. Kahn Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus
J. Clin. Endocrinol. Metab.,
February 1, 1998;
83(2):
604 - 608.
[Abstract][Full Text]
N. Porksen, B. Nyholm, J. D. Veldhuis, P. C. Butler, and O. Schmitz In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts
Am J Physiol Endocrinol Metab,
November 1, 1997;
273(5):
E908 - E914.
[Abstract][Full Text][PDF]
C. D. Saudek, W. C. Duckworth, A. Giobbie-Hurder, W. G. Henderson, R. R. Henry, D. E. Kelley, S. V. Edelman, F. J. Zieve, R. A. Adler, J. W. Anderson, et al. Implantable Insulin Pump vs Multiple-Dose Insulin for Non--Insulin-Dependent Diabetes Mellitus: A Randomized Clinical Trial
JAMA,
October 23, 1996;
276(16):
1322 - 1327.
[Abstract][PDF]
G. L. Wilson and S. P. LeDoux The Role of Chemicals in the Etiology of Diabetes Mellitus
Toxicol Pathol,
February 1, 1989;
17(2):
357 - 363.
[Abstract][PDF]
D. W. Erkelens, J. J. Albers, W. R. Hazzard, R. C. Frederick, and E. L. Bierman High-Density Lipoprotein-Cholesterol in Survivors of Myocardial Infarction
JAMA,
November 16, 1979;
242(20):
2185 - 2189.
[Abstract][PDF]
T. D. BIRD, J. L. TURNER, S. M. SUMI, and E. L. BIERMAN Abnormal Function of Endocrine Pancreas and Anterior Pituitary in Friedreich's Ataxia: Studies in a Family
Ann Intern Med,
April 1, 1978;
88(4):
478 - 481.
[Abstract][PDF]
S. M. GENUTH Insulin Secretion in Obesity and Diabetes: An Illustrative Case
Ann Intern Med,
December 1, 1977;
87(6):
714 - 716.
[Abstract][PDF]
J. Meyer, J. Sturis, M. Katschinski, R. Arnold, B. Goke, and M. M. Byrne Acute hyperglycemia alters the ability of the normal beta -cell to sense and respond to glucose
Am J Physiol Endocrinol Metab,
April 1, 2002;
282(4):
E917 - E922.
[Abstract][Full Text][PDF]
